Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Groups Uniting To Grow Global Regenerative Medicine Sector

This article was originally published in PharmAsia News

Executive Summary

South Korea, the U.S. and Japan are among the leading countries involved in the commercialization of stem cell therapies, with Japan’s Ministry of Economy, Trade and Industry (METI) estimating that the global regenerative medicines (RM) industry will grow strongly to reach a massive JPY53 trillion ($449 billion) by 2050. Groups in all three countries are now working closely to overcome the challenges in the sector, a recent conference in South Korea heard.

You may also be interested in...



Considering Growth Options For Asian Biotechs: IPO Vs M&A

Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.

Nanjing BioPoint Shoots For 2018 Double POC Launch; Seeks $10m

A China-based IVD company, spun out of an Australian medical research institute, is seeking investors to support its plans for the 2018 launch its first two point-of-care tests for patients with infectious diseases including HIV and viral hepatitis.

Local Expertise Key To Tackling China Market: AusBiotech Meeting

Speakers from the legal, corporate and contract research sectors discussed the fast-moving changes that are impacting the legal and regulatory aspects of doing business in China at the recent AusBiotech conference in Melbourne, providing a broad range of advice for Australian and other pharma and biotech companies wanting to enter the rapidly expanding Chinese life sciences market.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088780

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel